Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 3,302 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Circulatory System Clear all
Completed Phase 3 Interventional Results available

Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema

NCT01363440
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321), Macular Laser Photocoagulation
Drug · Procedure
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 30, 2016 · Synced Oct 10, 2026, 6:51 AM EDT
Recruiting Phase 1 Interventional

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT07148089
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
SGT-501
Drug
Lead sponsor
Solid Biosciences Inc.
Industry
Eligibility
7 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Cerebrospinal Fluid (CSF) Drainage Study

NCT01420978
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
CSF Diversion
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
View directory record Official record
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 10, 2026, 6:51 AM EDT
Completed No phase listed Observational

Safety & Efficacy Study of the Medtronic CoreValve® System-Treatment of Symptomatic Severe Aortic Stenosis With Significant Comorbidities in Extreme Risk Subjects Who Need Aortic Valve Replacement

NCT01675440
View directory record Official record
Conditions
Severe Aortic Stenosis
Interventions
Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
43
States / cities
Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Not yet recruiting No phase listed Observational

Pain Phenotyping of Rheumatic Diseases - An Observational Study

NCT07829497
View directory record Official record
Conditions
Rheumatic Diseases, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Arthritis, Spondylarthritis, Ankylosing Spondylarthritis, Rheumatoid Arthritis, Sjogren's Syndrome
Interventions
Bedside quantitative sensory testing
Device
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
9 Years to 85 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's Phenomenon

NCT00048776
View directory record Official record
Conditions
Raynaud's Disease
Interventions
Pletal
Drug
Lead sponsor
Otsuka America Pharmaceutical
Industry
Eligibility
5 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
19
States / cities
Anchorage, Alaska • Fresno, California • Madera, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2005 · Synced Oct 10, 2026, 6:51 AM EDT
Completed No phase listed Observational

Prospective Studies of the Natural History of Diabetes Mellitus and Its Complications in the Gila River Indian Community

NCT00339482
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
5 Years to 99 Years
Enrollment
12,647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1976
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Completed No phase listed Observational Results available

A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION

NCT00759174
View directory record Official record
Conditions
Optic Neuropathy, Ischemic
Interventions
No intervention
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
673 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Phase 2 Interventional Results available

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

NCT02292186
View directory record Official record
Conditions
TTR-mediated Amyloidosis
Interventions
Revusiran (ALN-TTRSC)
Drug
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Phase 2 Interventional

The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers

NCT00001873
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hematologic Neoplasm, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Isolex 300i plus MoAbs
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 55 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Percutaneous Endovascular Aneurysm Repair (PEVAR) Trial

NCT01070069
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
PEVAR (ProGlide closure), SEVAR (IntuiTrak), PEVAR (Prostar XL closure)
Device
Lead sponsor
Endologix
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
20
States / cities
Loma Linda, California • San Diego, California • Fort Lauderdale, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 10, 2026, 6:51 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Swab Sample Collection for the Detection of Bacterial Proteases in Wounds Assay

NCT01750203
View directory record Official record
Conditions
Chronic Wounds With Different Etiologies
Interventions
Swabs
Other
Lead sponsor
Systagenix Wound Management
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional

A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)

NCT02233088
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
ELM Group, ELM Classes, ELM Individual
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 72 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Phase 2Phase 3 Interventional

Lab Study of MQX-503 in Treatment of Raynaud's

NCT00253331
View directory record Official record
Conditions
Raynaud Disease, Raynaud Disease Secondary to Scleroderma, Raynaud Secondary to Other Autoimmune Disease
Interventions
topical organogel with nitroglycerin
Drug
Lead sponsor
MediQuest Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2007 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Lakeshore Examination of Activity and Disability Exercise Response Study

NCT02533882
View directory record Official record
Conditions
Multiple Sclerosis, Stroke
Interventions
Movement to Music, Adapted Yoga
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Phase 1 Interventional

Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies

NCT00446342
View directory record Official record
Conditions
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
Interventions
SNS-032 Injection
Drug
Lead sponsor
Sunesis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional Results available

Acellular Porcine Dermal Matrix Wound Dressing in the Management of Diabetic Foot Ulcers

NCT01353495
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
APM Graft (BIOTAPE XMTM), Wound Debridement
Device · Other
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Fresno, California • Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2021 · Synced Oct 10, 2026, 6:51 AM EDT
Not listed Phase 3 Interventional

Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

NCT00014339
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
Wobe-Mugos E, melphalan, prednisone, quality-of-life assessment
Drug · Procedure
Lead sponsor
Medsearch
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
19
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Action Selection and Arm Rehabilitation After Stroke

NCT02785419
View directory record Official record
Conditions
Stroke
Interventions
Arm Training with Action Selection
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 10, 2026, 6:51 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

NCT05206773
View directory record Official record
Conditions
Fabry Disease
Interventions
Venglustat (GZ402671), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
16 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Completed Not applicable Interventional

Evaluation of the Integrated Radio Frequency Denervation System to Improve Glycemic Control in Type 2 Diabetic Subjects

NCT04285554
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iRF System Hepatic Denervation
Device
Lead sponsor
Metavention
Industry
Eligibility
22 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Birmingham, Alabama • Stanford, California • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 10, 2026, 6:51 AM EDT
Active, not recruiting Phase 2 Interventional

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

NCT07354477
View directory record Official record
Conditions
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG), Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%)
Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 6:51 AM EDT
Completed No phase listed Observational

Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation

NCT00281801
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, Quality of Life Assessments
Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 10, 2026, 6:51 AM EDT